SCHEMBL2301167

SCHEMBL2301167

c1ccc(CNC2C[N]C2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.56
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
RAB9A P51151 1/20 0.52
ACHE P22303 6/20 0.51
BACE1 P56817 6/20 0.51
BCHE P06276 4/20 0.51
FYN P06241 1/20 0.51
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
OPRM1 P35372 2/20 0.46
OPRL1 P41146 2/20 0.46
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
HRH2 P25021 1/20 0.43
ADRA1B P35368 1/20 0.43
OPRK1 P41145 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092320 0.85 GRIN2B (0.54) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL663239 0.80 GRIN2B (0.74) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL5347556 0.80 GRIN2B (0.62) GRIN2BMEN1KMT2ARAB9AACHE
Hydrochloric Acid SCHEMBL2550113 0.78 MEN1 (0.78) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL1373877 0.77 GRIN2B (0.50) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL1373875 0.77 ACHE (0.51) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL433970 0.77 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL4173336 0.77 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL2954218 0.77 GRIN2B (0.69) GRIN2BMEN1KMT2ARAB9AACHE
SCHEMBL2095392 0.76 FUCA1 (0.50) GRIN2BFYNKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I GRIN2B 183/4885MEN1 3476/4885KMT2A 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.